Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavlo Gilchuk

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Cell|October 29, 2021
Pan-ebolavirus protective therapy by two multifunctional human antibodiesPavlo Gilchuk, Charles D Murin, Robert W Cross, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Biorxiv : the Preprint Server for Biology|April 28, 2021
A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeLaura VanBlargan, Lucas Adams, Zhuoming Liu, et al.
Cell|March 27, 2021
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinNaveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
The Journal of Clinical Investigation|August 4, 2025
Corrigendum to Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
The Journal of Clinical Investigation|June 22, 2021
Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
Cell|March 10, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individualsElaine C Chen, Pavlo Gilchuk, Seth J Zost, et al.
Nature Microbiology|May 9, 2018
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER regionAndrew I Flyak, Natalia Kuzmina, Charles D Murin, et al.
The Journal of Clinical Investigation|April 2, 2013
Discovering naturally processed antigenic determinants that confer protective T cell immunityPavlo Gilchuk, Charles T Spencer, Stephanie B Conant, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Cell|October 29, 2021
Pan-ebolavirus protective therapy by two multifunctional human antibodiesPavlo Gilchuk, Charles D Murin, Robert W Cross, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Biorxiv : the Preprint Server for Biology|April 28, 2021
A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeLaura VanBlargan, Lucas Adams, Zhuoming Liu, et al.
Cell|March 27, 2021
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinNaveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
The Journal of Clinical Investigation|August 4, 2025
Corrigendum to Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
The Journal of Clinical Investigation|June 22, 2021
Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interfaceSeth J Zost, Jinhui Dong, Iuliia M Gilchuk, et al.
Cell|March 10, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individualsElaine C Chen, Pavlo Gilchuk, Seth J Zost, et al.
Nature Microbiology|May 9, 2018
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER regionAndrew I Flyak, Natalia Kuzmina, Charles D Murin, et al.
The Journal of Clinical Investigation|April 2, 2013
Discovering naturally processed antigenic determinants that confer protective T cell immunityPavlo Gilchuk, Charles T Spencer, Stephanie B Conant, et al.
Pageof 8